- Home
- IRMD vs QURE Comparison
IRMD vs QURE Comparison
Compare IRMD & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRMD
- QURE
- Stock Information
- Founded
- IRMD 1992
- QURE 1998
- Country
- IRMD United States
- QURE Netherlands
- Employees
- IRMD N/A
- QURE N/A
- Industry
- IRMD Medical/Dental Instruments
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- IRMD Health Care
- QURE Health Care
- Exchange
- IRMD Nasdaq
- QURE Nasdaq
- Market Cap
- IRMD 737.7M
- QURE 860.8M
- IPO Year
- IRMD 2014
- QURE 2007
- Fundamental
- Price
- IRMD $59.17
- QURE $14.05
- Analyst Decision
- IRMD Strong Buy
- QURE Strong Buy
- Analyst Count
- IRMD 1
- QURE 8
- Target Price
- IRMD $60.00
- QURE $32.43
- AVG Volume (30 Days)
- IRMD 40.7K
- QURE 1.3M
- Earning Date
- IRMD 02-06-2025
- QURE 02-26-2025
- Dividend Yield
- IRMD 1.01%
- QURE N/A
- EPS Growth
- IRMD 13.16
- QURE N/A
- EPS
- IRMD 1.46
- QURE N/A
- Revenue
- IRMD $71,305,130.00
- QURE $28,587,000.00
- Revenue This Year
- IRMD $13.29
- QURE $153.92
- Revenue Next Year
- IRMD $10.76
- QURE N/A
- P/E Ratio
- IRMD $40.53
- QURE N/A
- Revenue Growth
- IRMD 13.23
- QURE N/A
- 52 Week Low
- IRMD $40.18
- QURE $3.73
- 52 Week High
- IRMD $59.31
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- IRMD 67.63
- QURE 48.03
- Support Level
- IRMD $55.36
- QURE $13.04
- Resistance Level
- IRMD $59.31
- QURE $14.32
- Average True Range (ATR)
- IRMD 1.65
- QURE 1.09
- MACD
- IRMD 0.30
- QURE -0.75
- Stochastic Oscillator
- IRMD 97.69
- QURE 16.40
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.